Comprehensive genome sequencing of SCLC tumors has revealed a high mutational load in this disease, with most tumors possessing inactivating mutations or deletions of RB1 and TP53, but few actionable targets have been identified5. This evidence concerns the gene RB1 and small cell lung carcinoma.